Antidepressant-like effects in various mice strains in the tail suspension test.
Several studies have reported rodent strain differences in the response to antidepressants in animal models of depression. The aim of the present study was to investigate the potential contribution of genetic factors to antidepressant response in an animal model of depression: the tail suspension test (TST). For this study four mice strains (Swiss and NMRI, two outbred strains and DBA/2 and C57BL/6J Rj, two inbred strains) were submitted to the TST after acute administration of five antidepressants: the tricyclic antidepressants (TCAs) imipramine and desipramine, the selective serotonin (5-HT) reuptake inhibitors (SSRIs) paroxetine and citalopram and the dopamine reuptake inhibitor bupropion. The C57BL/6J Rj strain had a longer baseline immobility time in comparison to the other strains. All antidepressants studied in this work decreased immobility time in the Swiss and C57BL/6J Rj strains. However, the Swiss strain displayed greater sensitivity to citalopram (from 2mg/kg) and C57BL/6J Rj to paroxetine (from 0.5mg/kg). This latter presented a greater size-effect with citalopram than with other strains and reached more than 60% from 8mg/kg. Moreover the size-effect of desipramine, paroxetine and bupropion in Swiss mice was greater than in the other strains in the TST. The NMRI and DBA/2 mice only responded to 5-HT reuptake inhibitors, both selective (paroxetine, citalopram) or non-selective (imipramine). The NMRI strain was more sensitive to imipramine and presented a size-effect (43% at 8mg/kg) superior to those of other strains. DBA/2 strain was more sensitive to citalopram than paroxetine and imipramine. Our results suggest that response to an antidepressant treatment is under control of genetic factors and that the strain of mouse is an important parameter to consider.
Ripoll
Nadège
N
Faculté de Médecine, EA 3256 Neurobiologie de l'anxiété et de la dépression, BP 53508, 1 rue Gaston Veil, F44035 Nantes, Cedex 01, France.
David
Denis Joseph Paul
DJ
Dailly
Eric
E
Hascoët
Martine
M
Bourin
Michel
M
D000704:Analysis of Variance; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D016642:Bupropion / Q000494:pharmacology; D015283:Citalopram / Q000494:pharmacology; D003863:Depression / Q000188:drug therapy; D003891:Desipramine / Q000494:pharmacology; D004195:Disease Models, Animal; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D019417:Hindlimb Suspension; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D051379:Mice / Q000235:genetics*; D008815:Mice, Inbred Strains / Q000235:genetics; D017374:Paroxetine / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013045:Species Specificity
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D016642:Bupropion; D015283:Citalopram; D003891:Desipramine; D018765:Dopamine Uptake Inhibitors; D007099:Imipramine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors